AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35945827
Drug: Prediction model
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction model for diagnosing CRC using hemoglobin-to-platelet ratio, fibrinogen-albumin ratio (FAR), albumin-globulin ratio (A/G), platelet-lymphocyte ratio, carcinoembryonic antigen (CEA), and thrombin time (TT).
Trial: 35945827
Drug: Prediction model
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction model for diagnosing CRC stage using prothrombin time (PT), TT, CEA, A/G, FAR, and hemoglobin-to-platelet ratio (HPR).
Trial: 35945827
Drug: Prediction model
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction model for diagnosing CRC grade using PT, TT, A/G, plateletcrit, FAR, and HPR.
Trial: 33637074
Drug: Parenteral ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Parenteral ibuprofen
Trial: 33608400
Drug: Inhaled sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled sedation strategy
Trial: 33608400
Drug: Intravenous sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sedation strategy
Trial: 33065813
Drug: Lurasidone 20-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 20-60 mg/d
Trial: 34294144
Drug: Baidu Jieduan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baidu Jieduan granules (twice a day for 14 days)
Trial: 34518313
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg orally twice daily and capivasertib orally twice daily on a 4-day on 3-day off schedule (DL1: 400 mg, DL-1: 320 mg)
Trial: 34518313
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg orally twice daily and capivasertib orally twice daily on a 4-day on 3-day off schedule
Trial: 32819292
Drug: Extracorporeal blood
RxNorm normalized name: Extracorporeal blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracorporeal blood purification (hemoadsorption) via resin-directed hemoperfusion using continuous renal replacement therapy (CVVH) for three sessions
Trial: 32381160
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 mg or placebo administered subcutaneously every 2 weeks, titrated to 150 mg if LDL-C remained ≥50 mg/dl.
Trial: 33881579
Drug: Inhalation Anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation Anesthesia (INHA) with desflurane (DES)
Trial: 33417284
Drug: Topical cetirizine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cetirizine 1% applied daily (1 mL) for 6 months
Trial: 33417284
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution applied daily (1 mL) for 6 months
Trial: 35843915
Drug: Lidocaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1 mg/kg and continuous infusion at 2 mg/kg/h)
Trial: 35843915
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (continuous infusion at 1.5 gr/kg)
Trial: 36113378
Drug: JR-142 at
RxNorm normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JR-142 at 0.25 mg/kg
Trial: 36113378
Drug: JR-142 at
RxNorm normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JR-142 at 0.5 mg/kg
Trial: 36113378
Drug: JR-142 at
RxNorm normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JR-142 at 1.0 mg/kg
Trial: 33713840
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care adapted for co-occurring disorders (CC-COD)
Trial: 33621809
Drug: Exenatide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (5 mcg, subcutaneously)
Trial: 32819740
Drug: 20-minute session
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-minute session with a certified therapy dog and handler
Trial: 32591475
Drug: Natalizumab 600
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Natalizumab 600 mg
Trial: 34138478
Drug: Hydrocortisone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (200 mg/d) for 7 days or until hospital discharge
Trial: 32967151
Drug: Tetraselmis chuii
RxNorm normalized name: tetraselmis chui extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetraselmis chuii microalgae supplementation (200 mg per day)
Trial: 32967151
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (lactose powder 200 mg per day)
Trial: 36279463
Drug: Proposed treatment
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed treatment in randomized experiments
Trial: 36368915
Drug: Group P
RxNorm normalized name: High mobility group protein HMGI-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group P (0 mg.kg-1 S-ketamine)
Trial: 36368915
Drug: Group S0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group S0.3 (0.3 mg.kg-1 S-ketamine)
Trial: 36368915
Drug: Group S0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group S0.5 (0.5 mg.kg-1 S-ketamine)
Trial: 36368915
Drug: Group S0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group S0.7 (0.7 mg.kg-1 S-ketamine)
Trial: 34975349
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) - Instruction of daily care (IDC) only
Trial: 32064970
Drug: 0.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/day omega-3 fatty acids from a plant-based fatty acid supplement
Trial: 34347895
Drug: articaine (4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: articaine (4% / 2 mL)
Trial: 34347895
Drug: tramadol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tramadol (100 mg/2 mL)
Trial: 34347895
Drug: dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexamethasone (8 mg/2 mL)
Trial: 34743963
Drug: 5% nanoHAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% nanoHAP dental lotion
Trial: 34743963
Drug: Placebo dental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dental lotion
Trial: 33323529
Drug: Poseltinib 5
RxNorm normalized name: Poseltinib
DrugBank: Poseltinib (DB16299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poseltinib 5 mg
Trial: 33323529
Drug: Poseltinib 10
RxNorm normalized name: Poseltinib
DrugBank: Poseltinib (DB16299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poseltinib 10 mg
Trial: 33323529
Drug: Poseltinib 30
RxNorm normalized name: Poseltinib
DrugBank: Poseltinib (DB16299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poseltinib 30 mg
Trial: 35667569
Drug: Monthly pegcetacoplan
RxNorm normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly pegcetacoplan treatment (AM)
Trial: 35667569
Drug: Bimonthly pegcetacoplan
RxNorm normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimonthly pegcetacoplan treatment (AEOM)
Trial: 35719221
Drug: LSMT (unilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSMT (unilateral lumbar PA mobilization at L‐4)
Trial: 35719221
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LSMT and SS
Trial: 33855653
Drug: Nimodipine 30
RxNorm normalized name: nimodipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 30 mg TID plus choline alphoscerate 600 mg BID
Trial: 33855653
Drug: Nimodipine 30
RxNorm normalized name: nimodipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 30 mg TID plus placebo BID
Trial: 35951060
Drug: Aerosol inhalation
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol inhalation combined with a vibration expectoration machine
Trial: 33829344
Drug: Lutetium-Octreotate (LO)
RxNorm normalized name: lutetium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutetium-Octreotate (LO) treatment
Trial: 39695768
Drug: Olaparib (PARP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (PARP inhibitor)
Trial: 35721170
Drug: XueBiJing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XueBiJing treatment (100 ml, q12 h for 5–7 days)
Trial: 35721170
Drug: XueBiJing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XueBiJing treatment and Placebo treatment
Trial: 34035871
Drug: Placebo (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (no LIPUS treatment).
Trial: 34035871
Drug: Low-Intensity Pulsed
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Intensity Pulsed Ultrasound (LIPUS) treatment.
Trial: 36252718
Drug: Dexamethasone (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (24 mg intravenously, perioperatively)
Trial: 33245746
Drug: Overall Cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall Cohort (Tofacitinib 10 mg BID predominantly)
Trial: 36136830
Drug: Parent-adolescent treatment
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-adolescent treatment group
Trial: 36136830
Drug: Parent only
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent only treatment group
Trial: 35389487
Drug: n-3-PUFA ethyl
RxNorm normalized name: N-ethyl-3-hydroxy-N,N-dimethylanilinium
DrugBank: Edrophonium (DB01010)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: n-3-PUFA ethyl esters (3.9 g/d)
Trial: 33434676
Drug: Ceftolozane/tazobactam 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftolozane/tazobactam 3 g q8h
Trial: 33434676
Drug: Meropenem 1
RxNorm normalized name: meropenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 1 g q8h
Trial: 34332028
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 2400 mg/day and working memory training for 25 days
Trial: 32368942
Drug: Elastic bandage
RxNorm normalized name: elastic bandage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elastic bandage treatment
Trial: 33135094
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for smoking cessation and guideline-based inhaler pharmacotherapy for newly diagnosed patients
Trial: 35075598
Drug: LLLT-MTA (Low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LLLT-MTA (Low Level Laser Therapy with MTA)
Trial: 32703779
Drug: Pirfenidone plus
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone plus inhaled N-acetylcysteine 352.4 mg twice daily
Trial: 32703779
Drug: Pirfenidone plus
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone plus inhaled N-acetylcysteine
Trial: 32782200
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy alone (CTx)
Trial: 32782200
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant therapy (noTx)
Trial: 32782200
Drug: Adjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemoradiotherapy (CRT) with radiation dose ≥54 Gy
Trial: 32926117
Drug: Transcranial Low-Level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial Low-Level Light Therapy (LLLT)
Trial: 32926117
Drug: Sham Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham Therapy
Trial: 35544437
Drug: Text-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text-based intervention focused on non-vaccine-related COVID-19 preventive health measures
Trial: 32084142
Drug: IFN Nebulization
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN Nebulization 2 (2 μg/kg)
Trial: 32084142
Drug: IFN Nebulization
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN Nebulization 1 (1 μg/kg)
Trial: 36471382
Drug: Teleconsultations by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teleconsultations by specialists for neurology and palliative medicine
Trial: 33574009
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL LR-PRP injection (single dose)
Trial: 33574009
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL LR-PRP injection (double dose)
Trial: 33574009
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (single and double dose)
Trial: 35339102
Drug: 700/35 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700/35 mg foslevodopa/foscarbidopa subcutaneous infusion over 24 h
Trial: 35339102
Drug: 350/87.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350/87.5 mg LD/CD administered over 16 h followed by two 100/25 mg LD/CD oral doses
Trial: 34104878
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (CP) therapy
Trial: 32558416
Drug: UDCA 5
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 5 mg/kg/dose every 12 hours orally with phototherapy
Trial: 32558416
Drug: UDCA 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 7.5 mg/kg/dose every 12 hours orally with phototherapy
Trial: 32517477
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (weekly for five consecutive weeks)
Trial: 32517477
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (pre-treatment effect)
Trial: 33971993
Drug: Pecan nuts
RxNorm normalized name: Pecan nuts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pecan nuts group (30 g/d of pecans + healthy diet)
Trial: 33971993
Drug: Extra-virgin olive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-virgin olive oil group (30 ml/d of extra-virgin olive oil + healthy diet)
Trial: 33206059
Drug: Recommended care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended care with telerehabilitation (including a weekly group teleconference session)
Trial: 33261578
Drug: Animal-Assisted Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal-Assisted Therapy (AAT) with a bird for eight weeks
Trial: 32624377
Drug: Transdermal buprenorphine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transdermal buprenorphine patch (10 μg/h)
Trial: 32624377
Drug: Oral celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral celecoxib
Trial: 36103665
Drug: Restylane Lyft
RxNorm normalized name: Restylane
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restylane Lyft (1 ml on day 1, re-treatment of 0.5 ml at month 12)
Trial: 36103665
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control (1 ml offered at month 6)
Trial: 33798509
Drug: Dextrose gel
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose gel (200 mg/kg)
Trial: 35144326
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual + Rhemercise (n=63)
Trial: 35144326
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual only (n=63)
Trial: 34874419
Drug: High-flow oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow oxygen therapy through a nasal cannula
Trial: 33642340
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Vitamin C
Trial: 33351209
Drug: VITILSI© gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VITILSI© gel 2 x day
Trial: 33351209
Drug: VITILSI© gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VITILSI© gel 2 x day + Bioskin© 1 x week
Trial: 35302901
Drug: Intraoperative injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative injection of autologous microfragmented adipose tissue
Trial: 35302901
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no injection of autologous microfragmented adipose tissue)
Trial: 33221969
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + nintedanib
Trial: 32698123
Drug: α-lactalbumin (LA)
RxNorm normalized name: alpha-lactalbumin (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-lactalbumin (LA) 40 g
Trial: 32698123
Drug: Collagen peptide
RxNorm normalized name: Procollagen peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen peptide (CP) 40 g
Trial: 35182721
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg i.v. on day 1 with neoadjuvant carboplatin and nab-paclitaxel
Trial: 32861716
Drug: C2238 ANP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C2238 ANP allele (homozygous CC)
Trial: 34585595
Drug: loteprednol‐etabonate 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loteprednol‐etabonate 0.5% twice daily for 14 days tapered to once daily for 14 days, and then twice weekly for 28 days
Trial: 32722454
Drug: 8% carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% carbohydrate (CHO) solution (5 mL/kg/bw)
Trial: 32722454
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) solution (flavour and appearance-matched, 5 mL/kg/bw)
Trial: 89012353
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B immune globulin and vaccine on schedule
Trial: 89012353
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B immune globulin and vaccine off schedule
Trial: 34699967
Drug: Albuterol/budesonide (180/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol/budesonide (180/160 µg)
Trial: 34699967
Drug: Albuterol/budesonide
RxNorm normalized name: ALBUTEROL/BUDESONIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol/budesonide
Trial: 34397827
Drug: Inhalation anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anesthesia (IH)
Trial: 34570180
Drug: Methylphenidate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (10 mg, twice daily)
Trial: 32175680
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of edaravone with taurine
Trial: 33562090
Drug: Fermented powdered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented powdered soy product (12.5 g each, 2 packets daily)
Trial: 36228310
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day (Group 1)
Trial: 36228310
Drug: 2.5 mg/day
RxNorm normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/day (Group 2)
Trial: 36228310
Drug: 5 mg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/week (Group 3)
Trial: 36099688
Drug: Acceptance-enhanced behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance-enhanced behavior therapy for TTM (AEBT‐TTM)
Trial: 38761558
Drug: Psychoeducation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducation and supportive therapy (PST)
Trial: 34050429
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural analgesia (TEA) with continuous epidural bupivacaine and sufentanil infusion
Trial: 34050429
Drug: Paravertebral analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paravertebral analgesia (PVA) with continuous paravertebral bupivacaine infusion and intravenous morphine
Trial: 35590794
Drug: Ringer’s solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer’s solution
Trial: 35590794
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no liquid administered)
Trial: 34656955
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg MOFs daily for 3 months